http://rdf.ncbi.nlm.nih.gov/pubchem/patent/AU-2014227490-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_f52c68e4149a6c462b850d4e7cc2b2f9 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-569 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-57 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-58 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-585 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-20 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-565 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-567 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-28 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P5-28 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P15-18 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P15-00 |
| filingDate | 2014-09-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_308dc140a43b02da5436c25099126afa http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8cf3997600ac86bb6d62612a507133c9 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_fa6539981fa8a849cbc0eacb1c3b6580 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_55b801433ba620f5ac48258762ad49de |
| publicationDate | 2014-10-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | AU-2014227490-A1 |
| titleOfInvention | Pharmaceutical combination of ethinylestradiol and drospirenone for use as a contraceptive |
| abstract | H:\tzm\Interwoven\NRPortbl\DCC\TZM\6753328_l.DOC- 18/09/2014 PHARMACEUTICAL COMBINATION OF ETHINYLESTRADIOL AND DROSPIRENONE FOR USE AS A CONTRACEPTIVE A pharmaceutical composition comprises, as a first active agent, 6P, 7P, 15p, 16p dimethylene-3-oxo-17a-pregen-4-ene-21, 17-carbolactone (drospirenone) in an amount corresponding to a daily dosage, on administration of the composition, of from about 2 mg to about 4 mg, and, as a second active agent, 17a-ethinylestradiol (ethinylestradiol) in an amount corresponding to a daily dosage of from about 0.01 mg to about 0.05 mg, together with one or more pharmaceutically acceptable carriers or excipients. In a specific embodiment, the composition consists of a number of separately packaged and individually removable daily dosage units placed in a packaging unit and intended for oral administration for a period of at least 21 consecutive days, wherein said daily dosage units comprise the combination of drospirenone and ethinylestradiol. The composition may further comprise 7 or less daily dosage units containing no active agent or containing ethinylestradiol alone. |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2016171543-A1 |
| priorityDate | 1999-08-31-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 106.